Related Experiment Video

Updated: Jul 20, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Frequency and comparative analysis of hapatitis D in petients seeking treatment for hepatitis B

Bader Faiyaz Zuberi1, Muhmmad Saeed Quraishy, Salahuddin Afsar

  • 1Department of Medicine, Dow University of Health Sciences, Karachi. bader@zuberi.com.pk

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|September 2, 2006
PubMed

Insights

Hepatitis D virus (HDV) infection is common in patients with Hepatitis B virus (HBV) infection, affecting 26.8% in this study. Screening for HDV is crucial before initiating HBV treatment.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis B virus (HBV) infection is a global health concern.
  • Hepatitis D virus (HDV) is a unique RNA virus that requires HBV for replication.
  • Coinfection with HDV can lead to more severe liver disease progression.

Purpose of the Study:

  • To determine the prevalence of HDV among HBV-infected patients.
  • To compare clinical and biochemical characteristics between HDV-positive and HDV-negative HBV patients.

Main Methods:

  • A cross-sectional study was conducted from July 2003 to June 2005.
  • 246 HBsAg-positive patients were enrolled and tested for anti-HDV antibodies.
  • Patients were categorized into HDV-positive and HDV-negative groups for comparative analysis of liver function tests and viral markers.

Main Results:

  • HDV infection was detected in 66 (26.8%) of the 246 patients.
  • Significant differences were observed in SGPT, albumin levels, and the frequency of HBeAg, anti-HBc IgM, and HBV DNA between the groups.
  • No significant difference in cirrhosis frequency or stage was noted between HDV-positive and HDV-negative patients.

Conclusions:

  • HDV infection is prevalent in HBV-infected patients within this cohort.
  • Screening for HDV is recommended for all HBV patients prior to treatment decisions to guide management strategies.
Abstract

More Related Videos

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...